Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | PPID | Q08752 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15338744 | 0.89 | L3MBTL1 (0.55) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL12330833 | 0.88 | L3MBTL1 (0.54) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL12467295 | 0.87 | MAPT (0.52) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL4197742 | 0.85 | SMN1; SMN2 (0.50) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL3528783 | 0.84 | ANPEP (0.50) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL13881122 | 0.82 | L3MBTL1 (0.48) | MAPTL3MBTL1ATMEPHX1SMN1; SMN2 | |
| SCHEMBL30817744 | 0.80 | HCRTR2 (0.48) | MAPTL3MBTL1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL7206283 | 0.79 | MAPK1 (0.76) | MAPTL3MBTL1ATMSMN1; SMN2ANPEP | |
| SCHEMBL5175905 | 0.79 | MAPK1 (0.76) | MAPTL3MBTL1ATMSMN1; SMN2ANPEP | |
| SCHEMBL6445570 | 0.79 | MAPK1 (0.76) | MAPTL3MBTL1ATMSMN1; SMN2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1396492-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7807677-B2 | HIV protease inhibitors | MEDIVIR AB (SE) | 2010-10-05 | — | — | US | disclosed |
| EP-1851193-B1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080249102-A1 | Hiv Protease Inhibitors | MEDIVIR AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1851193-A1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007048557-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2006084688-A1 | HIV protease inhibitors | MEDIVIR AB (SE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249102-A1 | Hiv Protease Inhibitors | SERPINB1, ANPEP, XPNPEP1 | MAPT 3110/4885L3MBTL1 536/4885ATM 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.